"Amifampridine"[MeSH] - Search Results

Year	Number of Results
1980	2
1981	1
1982	6
1983	14
1984	11
1985	14
1986	15
1987	15
1988	13
1989	13
1990	16
1991	13
1992	11
1993	14
1994	20
1995	14
1996	13
1997	5
1998	14
1999	4
2000	4
2001	7
2002	6
2003	10
2004	10
2005	3
2006	9
2007	8
2008	5
2009	6
2010	14
2011	10
2012	9
2013	6
2014	7
2015	7
2016	11
2017	7
2018	9
2019	7
2020	7
2021	7
2022	3
2023	1
2024	2

1

Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes-A Comprehensive Review.

Ohno K, Ohkawara B, Shen XM, Selcen D, Engel AG. Ohno K, et al. Int J Mol Sci. 2023 Feb 13;24(4):3730. doi: 10.3390/ijms24043730. Int J Mol Sci. 2023. PMID: 36835142 Free PMC article. Review.

2

Amifampridine for the treatment of Lambert-Eaton myasthenic syndrome.

Oh SJ. Oh SJ. Expert Rev Clin Immunol. 2019 Oct;15(10):991-1007. doi: 10.1080/1744666X.2020.1670061. Epub 2019 Sep 30. Expert Rev Clin Immunol. 2019. PMID: 31533480 Review.

3

Amifampridine for the Management of Lambert-Eaton Myasthenic Syndrome: A New Take on an Old Drug.

Yoon CH, Owusu-Guha J, Smith A, Buschur P. Yoon CH, et al. Ann Pharmacother. 2020 Jan;54(1):56-63. doi: 10.1177/1060028019864574. Epub 2019 Jul 18. Ann Pharmacother. 2020. PMID: 31319693 Review.

4

Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome.

Mantegazza R. Mantegazza R. Expert Rev Clin Pharmacol. 2019 Nov;12(11):1013-1018. doi: 10.1080/17512433.2019.1681972. Epub 2019 Oct 22. Expert Rev Clin Pharmacol. 2019. PMID: 31639317 Review.

5

Reply.

Sanders DB, Harati Y, Juel VC, Lou JS, Marburger T, Pascuzzi RM, Peltier AC, Richman DP, Smith AG. Sanders DB, et al. Muscle Nerve. 2018 May;57(5):E130-E131. doi: 10.1002/mus.26089. Epub 2018 Mar 1. Muscle Nerve. 2018. PMID: 29406616 No abstract available.

6

Neuromuscular junction disorders beyond myasthenia gravis.

Oh SJ. Oh SJ. Curr Opin Neurol. 2021 Oct 1;34(5):648-657. doi: 10.1097/WCO.0000000000000972. Curr Opin Neurol. 2021. PMID: 34914667 Review.

7

Amifampridine to treat Lambert-Eaton myasthenic syndrome.

Oh SJ. Oh SJ. Drugs Today (Barc). 2020 Oct;56(10):623-641. doi: 10.1358/dot.2020.56.10.3137144. Drugs Today (Barc). 2020. PMID: 33185628 Clinical Trial.

8

Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.

Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, Alsharabati M, Dimachkie M, Blanco JM, Brannagan T, Lavrnić D, Shieh PB, Vial C, Meisel A, Komoly S, Schoser B, Sivakumar K, So Y; LEMS Study Group. Oh SJ, et al. Muscle Nerve. 2016 May;53(5):717-25. doi: 10.1002/mus.25070. Epub 2016 Mar 3. Muscle Nerve. 2016. PMID: 26852139 Clinical Trial.

9

Amifampridine Phosphate (Firdapse) Is Effective in a Confirmatory Phase 3 Clinical Trial in LEMS.

Shieh P, Sharma K, Kohrman B, Oh SJ. Shieh P, et al. J Clin Neuromuscul Dis. 2019 Mar;20(3):111-119. doi: 10.1097/CND.0000000000000239. J Clin Neuromuscul Dis. 2019. PMID: 30801481 Free PMC article. Clinical Trial.

10

Lambert-Eaton Myasthenic Syndrome and Botulism.

Raja SM. Raja SM. Continuum (Minneap Minn). 2022 Dec 1;28(6):1596-1614. doi: 10.1212/CON.0000000000001205. Continuum (Minneap Minn). 2022. PMID: 36537971 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

387 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

387 results

Results by year